Corrigendum to “Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome”

Corrigendum to “Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome”

Molecular Therapy 24,
1159 (June 2016). doi:10.1038/mt.2016.96

Source: Molecular Therapy - June 20, 2016 Category: Genetics & Stem Cells Source Type: research